Tilray Falls On Big Q4 Earnings, Sales Miss

Tilray, Inc. TLRY reported fourth-quarter losses at $2.14 per share, which does not compare to the 35-cent loss estimate. The company reported sales $46.936 million, which missed the analysts estimate of $55.92 million.

Tilray reported fourth-quarter total cannabis kilogram equivalents sold 15.039K kg and adjusted EBITDA loss of $35.3 million.

"Our full year results demonstrate strong sales growth momentum, which we expect to continue in 2020," said CEO Brendan Kennedy. "Like our peers, we have faced industry challenges, but we remain committed to driving long-term value for our shareholders. Tilray has a diversified business model comprised of global medical, Canada adult-use and hemp products which positions us well in the current volatile market environment."

Tilray's stock was down 10% in Monday's after-hours session after closing at $15.25 per share. The stock has a 52-week high of $82.81 and a 52-week low of $13.20.

Related Links:

Tilray, Aurora Cannabis Layoffs May Signal Industrywide Problem

Digesting What Cannabis 2.0 Means For The Industry: 'A Lot Of Opportunity'

TLRY Logo
TLRYTilray Brands Inc
$0.4081-0.46%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
3.20
Growth
22.34
Quality
Not Available
Value
84.15
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Comments
Loading...